(Total Views: 490)
Posted On: 06/12/2022 12:43:26 PM
Post# of 148899
This points to the biggest weakness in all these FDA trials, they are not adaptive. Especially when people are dying, why are the trials so rigid?
Our CD12 trial would have been successful if doctors had the ability to see the patient getting worse after LL is stopped and then adjust the trial to give more doses to patients that didn't respond and walk at two weeks.
We all adjust our own dose of medicine all the time at home. Duh.
Our CD12 trial would have been successful if doctors had the ability to see the patient getting worse after LL is stopped and then adjust the trial to give more doses to patients that didn't respond and walk at two weeks.
We all adjust our own dose of medicine all the time at home. Duh.
Quote:
The dosing issue can be addressed simply by closing the loop more frequently and dosing based on the feedback.
(4)
(0)Scroll down for more posts ▼
